Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lyra Therapeutics (LYRA) Income from Continuing Operations (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Income from Continuing Operations for 5 consecutive years, with 5984000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Income from Continuing Operations rose 49.6% to 5984000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 32947000.0, a 66.25% increase, with the full-year FY2024 number at 93435000.0, down 49.07% from a year prior.
  • Income from Continuing Operations was 5984000.0 for Q3 2025 at Lyra Therapeutics, up from 7437000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 5984000.0 in Q3 2025 to a low of 48131000.0 in Q2 2024.
  • A 5-year average of 14571631.58 and a median of 13617000.0 in 2021 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: crashed 208.18% in 2024, then skyrocketed 84.55% in 2025.
  • Lyra Therapeutics' Income from Continuing Operations stood at 13617000.0 in 2021, then fell by 4.44% to 14222000.0 in 2022, then decreased by 6.57% to 15156000.0 in 2023, then rose by 27.56% to 10979000.0 in 2024, then soared by 45.5% to 5984000.0 in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Income from Continuing Operations are 5984000.0 (Q3 2025), 7437000.0 (Q2 2025), and 8547000.0 (Q1 2025).